SAGE Therapeutics Inc SKYLARK Study Topline Data Call Transcript
Good morning. Welcome to Sage Therapeutics conference call to discuss top line results from the SKYLARK Study. (Operator Instructions) This call is being webcast live on the Investors & Media section of Sage's website at sagerx.com. This call is the property of Sage Therapeutics, and recording, reproduction or transmission of this call without the express written consent of Sage Therapeutics is strictly prohibited. Please note that this call is being recorded.
I would now like to introduce Helen Rubinstein, Director of Investor Relations at Sage.
Good morning, and thank you for joining Sage Therapeutics conference call to discuss top line results from the Phase III SKYLARK Study of zuranolone in postpartum depression. Before we begin, I encourage everyone to go to the Investors & Media section of our website at sagerx.com, where you can find the press release and slides related to today's call.
I'd like to point out that we will be making forward-looking statements, which are
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |